


# Nanotechnology in the UK & Europe



## Advances in Nanotechnology: New Opportunities and Challenges

London Office

Conference Room 6, 30<sup>th</sup> Floor

28 March 2007 ■ 09:30–12:30

### Agenda

**0930**

#### **1. INTRODUCTION**

Liz Driver, Arnold & Porter (UK) LLP, London

- 1.1 Definition
- 1.2 Scope
- 1.3 Potential adverse impacts
- 1.4 Approach to risk management

**0950**

#### **2. GLOBAL MARKETS AND CURRENT AND PREDICTED VALUES**

Dr Alessandro Rospigliosi, Ludgate Investments Limited, a private equity group

- 2.1 Investing in nanotechnology - seed capital, venture capital and private equity funding
- 2.2 Sectors and applications of nanotechnology primed for investment
- 2.3 Current and future values of investments and markets (UK, EU, global)
- 2.4 Perceived risks for investors
- 2.5 Specific examples of nanotechnology investments

**1020**

#### **3. NANOTECHNOLOGY INTELLECTUAL PROPERTY ISSUES**


Clive Thorne, Arnold & Porter (UK) LLP, London

- 3.1 Intellectual property protection
- 3.2 Patent issues
- 3.3 Exploitation of rights

**1040**

**COFFEE**

## Nanotechnology in the UK & Europe



### Advances in Nanotechnology: New Opportunities and Challenges

London Office

Conference Room 6, 30<sup>th</sup> Floor

28 March 2007 ■ 09:30–12:30

#### Agenda (continued)

**1100**

#### **4. POTENTIAL SAFETY ISSUES**

Professor David Williams, Chairman of EC Scientific Committee on Emerging and Newly Identified Health Risks

- 4.1 Risk assessment: adequacy of current methodologies and development of new methodologies.
- 4.2 Major gaps in knowledge needed for proper risk assessment.

**1140**

#### **5. RISK GOVERNANCE/REGULATION**

Lincoln Tsang, Arnold & Porter (UK) LLP, London

- 5.1 Diversity in approach between countries and between agencies
- 5.2 Are nanotech molecules new chemical entities?
- 5.3 Self-regulation by industry

**1210**

#### **6. MANAGING UNCERTAINTY AND RISK**

Fern O'Brian, Arnold & Porter LLP, Washington, DC

- 6.1 Potential for product liability litigation
- 6.2 Design defect
- 6.3 Adequacy of testing
- 6.4 Compliance with evolving regulatory requirements
- 6.5 Insurance implications

#### **7. GENERAL DISCUSSION**

**1230**

**LUNCH**